Koichiro Minami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4892722/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Senolytics prevent mt-DNA-induced inflammation and promote the survival of aged organs following transplantation. Nature Communications, 2020, 11, 4289.	5.8	125
2	microRNA-145 Mediates the Inhibitory Effect of Adipose Tissue-Derived Stromal Cells on Prostate Cancer. Stem Cells and Development, 2016, 25, 1290-1298.	1.1	87
3	Adipose-derived stromal cells inhibit prostate cancer cell proliferation inducing apoptosis. Biochemical and Biophysical Research Communications, 2014, 446, 1102-1107.	1.0	46
4	A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder. Disease Markers, 2018, 2018, 1-6.	0.6	39
5	A Novel Combination RNAi toward Warburg Effect by Replacement with miR-145 and Silencing of PTBP1 Induces Apoptotic Cell Death in Bladder Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 179.	1.8	37
6	C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma – A data from multi-institutional study in Japan. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 812.e1-812.e8.	0.8	29
7	Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy. Annals of Surgical Oncology, 2017, 24, 2787-2793.	0.7	28
8	Intravesical administration of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft. Oncotarget, 2015, 6, 21628-21635.	0.8	27
9	MicroRNAâ€∎43/Musashiâ€⊋/ <scp>KRAS</scp> cascade contributes positively to carcinogenesis in human bladder cancer. Cancer Science, 2019, 110, 2189-2199.	1.7	27
10	The combination of preoperative platelet count and neutrophil lymphocyte ratio as a prognostic indicator in localized renal cell carcinoma. Oncotarget, 2017, 8, 110311-110325.	0.8	24
11	Mast cells regulate CD4+ T-cell differentiation in the absence of antigen presentation. Journal of Allergy and Clinical Immunology, 2018, 142, 1894-1908.e7.	1.5	23
12	Targeting of intragraft reactive oxygen species by APP-103, a novel polymer product, mitigates ischemia/reperfusion injury and promotes the survival of renal transplants. American Journal of Transplantation, 2020, 20, 1527-1537.	2.6	21
13	Recipient sex and estradiol levels affect transplant outcomes in an age-specific fashion. American Journal of Transplantation, 2021, 21, 3239-3255.	2.6	21
14	The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma. Oncotarget, 2017, 8, 113248-113257.	0.8	20
15	Targeting ageâ€specific changes in CD4 ⁺ T cell metabolism ameliorates alloimmune responses and prolongs graft survival. Aging Cell, 2021, 20, e13299.	3.0	16
16	Could Transurethral Resection of the Prostate Using the TURis System Take Over Conventional Monopolar Transurethral Resection of the Prostate? A Randomized Controlled Trial and Midterm Results. Urology, 2014, 84, 405-411.	0.5	13
17	The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): A new treatment option for invasive bladder cancer patients with lymph node metastasis. International Journal of Oncology, 2014, 44, 1895-1903.	1.4	13
18	Novel Bladder Preservation Therapy with Osaka Medical College Regimen. Journal of Urology, 2015, 193, 443-450.	0.2	13

#	Article	IF	CITATIONS
19	Rapamycin Prolongs Graft Survival and Induces CD4+IFN-Î ³ +IL-10+ Regulatory Type 1 Cells in Old Recipient Mice. Transplantation, 2018, 102, 59-69.	0.5	13
20	The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in Japan. Annals of Surgical Oncology, 2019, 26, 2994-3004.	0.7	13
21	Changes of T-cell Immunity Over a Lifetime. Transplantation, 2019, 103, 2227-2233.	0.5	13
22	The Anti-Proliferative Effect of Boron Neutron Capture Therapy in a Prostate Cancer Xenograft Model. PLoS ONE, 2015, 10, e0136981.	1.1	12
23	CTLA4-Ig prolongs graft survival specifically in young but not old mice. American Journal of Transplantation, 2021, 21, 488-502.	2.6	10
24	Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort. World Journal of Urology, 2020, 38, 3183-3190.	1.2	5
25	Taurodeoxycholic acid and valine reverse obesity-associated augmented alloimmune responses and prolong allograft survival. American Journal of Transplantation, 2022, 22, 402-413.	2.6	5
26	E74-like factor inhibition induces reacquisition of hormone sensitiveness decreasing period circadian protein homolog 1Âexpression in prostate cancer cells. Prostate International, 2015, 3, 16-21.	1.2	3
27	Recall features and allorecognition in innate immunity. Transplant International, 2018, 31, 6-13.	0.8	3
28	Influence of the Body Mass Index and its Effect on Tumor Characteristics and Survival among a Population with Access to Surgical Management of Upper Tract Urothelial Carcinoma. Current Urology, 2019, 12, 201-209.	0.4	3
29	Distinct effect of body mass index by sex as a prognostic factor in localized renal cell carcinoma treated with nephrectomy ~ data from a multi-institutional study in Japan ~. BMC Cancer, 2021, 21, 201.	1.1	3
30	Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer. International Journal of Oncology, 2019, 54, 167-176.	1.4	1
31	Successful Treatment of Antibody-Mediated Rejection by De Novo Donor Specific Antibody After Primary Renal Transplantation in a Recipient From a Cadaveric Donor: A Case Report. Transplantation Proceedings, 2020, 52, 1928-1930.	0.3	0